Literature DB >> 7011819

Renal effect of SB 7505: a double-blind study.

G F Melloni, G M Minoja, G Scorazzati, R Bauer, B Brusoni, P Ghirardi.   

Abstract

Two groups of 20 patients with no evidence of cardiovascular, hepatic, renal or gastrointestinal failure were treated orally for five days with placebo or SB 7505 100 mg/day. No change was observed in heart rate or blood pressure. Urine output, the excretion of Na, K and Cl, and creatinine clearance were significantly increased.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7011819     DOI： 10.1007/bf00561945

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  2 in total

1.  99mTc-DTPA(Sn) dry-kit preparation. Quality control and clearance studies.

Authors:  V Kempi; R B Persson
Journal:  Nucl Med (Stuttg)       Date:  1975-01-31

2.  Non-invasive evaluation of left ventricular function through systolic time intervals following oral administration of SB 7505 in man.

Authors:  L Dei Cas; C Manca; G Vasini; M Mansour; B Bernardini; O Visioli
Journal:  Arzneimittelforschung       Date:  1980
  2 in total
  9 in total

Review 1.  Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  J M Henwood; P A Todd
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

2.  Renal and neurohumoral effects of ibopamine and metoclopramide in normal man.

Authors:  A R Girbes; D J van Veldhuisen; A J Smit; A Drent-Bremer; S Meijer; W D Reitsma
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

3.  Effect of ibopamine on heart rate and spontaneous premature ventricular beats in patients with angina pectoris.

Authors:  E Montani; M O Triulzi; G C Maggi
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Clinical tolerability of ibopamine hydrochloride (SB 7505).

Authors:  G F Melloni; R Melloni; G M Minoja; G Scarazzati; G C Bruni; P Loreti; R Bauer
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Effect of the orally absorbed dopamine analogue N-methyldopamine diisobutyric ester on plasma prolactin levels.

Authors:  G Lombardi; A Tommaselli; C Fariello; A Quattrone; L Annunziato
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Effect of ibopamine on peripheral haemodynamics.

Authors:  C Longhini; G F Musacci; L Ansani; T Toselli; M Artioli; L Bianco; P Ghirardi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.

Authors:  P Ghirardi; B Brusoni; M Mangiavacchi; L Bianco; J Col; M Metra; L Dei Cas
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

8.  Ibopamine in very severe congestive heart failure: pilot haemodynamic invasive assessment.

Authors:  J Col; E Mievis; M Reynaert
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure.

Authors:  L Dei Cas; M Metra; S Nodari; S Riva; C Manca; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.